---
title: 'The risk of second malignancies following prostate cancer radiotherapy in
  the era of conformal radiotherapy: aÂ statement of the Prostate Cancer Working Group
  of the German Society of Radiation Oncology (DEGRO)'
date: '2024-08-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39196366/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240828182648&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: A significant number of prostate cancer patients are long-term survivors
  after primary definitive therapy, and the occurrence of late side effects, such
  as second primary cancers, has gained interest. The aim of this editorial is to
  discuss the most current evidence on second primary cancers based on six retrospective
  studies published in 2021-2024 using large data repositories not accounting for
  all possible confounding factors, such as smoking or pre-existing comorbidities.
  Overall, ...
disable_comments: true
---
A significant number of prostate cancer patients are long-term survivors after primary definitive therapy, and the occurrence of late side effects, such as second primary cancers, has gained interest. The aim of this editorial is to discuss the most current evidence on second primary cancers based on six retrospective studies published in 2021-2024 using large data repositories not accounting for all possible confounding factors, such as smoking or pre-existing comorbidities. Overall, ...